HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 57298

HXB2 Location  Gag(77-86)   Gag Epitope Map
View variants at this location
Epitope SLYNTVATLY   Epitope Alignment
Variants
SLYNTVAvLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLYNTiATLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLYNTiAvLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLfNTVATLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLfNTiAvLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLfNTVAvLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLfNTiATLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
Epitope Name SY10
Species (MHC/HLA human(A*02)

Variant Details

Showing all: 7 variant(s).


Variant ID.  2988
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLYNTVAvLY
Mutations T/V
Epitope Location T8V
HXB2 Location T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLYNTVAvLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients. The authors refer to all T84V mutation-containing peptides as escapes.


Variant ID.  2989
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLYNTiATLY
Mutations V/I
Epitope Location V6I
HXB2 Location V82I
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLYNTiATLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all V82I mutation-containing peptides as escapes.


Variant ID.  2990
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLYNTiAvLY
Mutations V/I T/V
Epitope Location V6I T8V
HXB2 Location V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLYNTiAvLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients. The authors refer to all V82I and T84V mutation-containing peptides as escapes.


Variant ID.  2991
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLfNTVATLY
Mutations Y/F
Epitope Location Y3F
HXB2 Location Y79F
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLfNTVATLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all Y79F mutation-containing peptides as escapes.


Variant ID.  2992
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLfNTiAvLY
Mutations Y/F V/I T/V
Epitope Location Y3F V6I T8V
HXB2 Location Y79F V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLfNTiAvLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all Y79F, V82I and T84V mutation-containing peptides as escapes.


Variant ID.  2993
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLfNTVAvLY
Mutations Y/F T/V
Epitope Location Y3F T8V
HXB2 Location Y79F T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLfNTVAvLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients. The authors refer to all Y79F mutation-containing peptides as escapes.


Variant ID.  2994
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLfNTiATLY
Mutations Y/F V/I
Epitope Location Y3F V6I
HXB2 Location Y79F V82I
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLfNTiATLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all Y79F mutation-containing peptides as escapes.

References

Tenzer2009 Stefan Tenzer, Edmund Wee, Anne Burgevin, Guillaume Stewart-Jones, Lone Friis, Kasper Lamberth, Chih-hao Chang, Mikkel Harndahl, Mirjana Weimershaus, Jan Gerstoft, Nadja Akkad, Paul Klenerman, Lars Fugger, E. Yvonne Jones, Andrew J. McMichael, Søren Buus, Hansjörg Schild, Peter van Endert, and Astrid K. N. Iversen. Antigen Processing Influences HIV-Specific Cytotoxic T Lymphocyte Immunodominance. Nat. Immunol., 10(6):636-646, Jun 2009. PubMed ID: 19412183. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Operated by Los Alamos National Security, LLC, for the U.S. Department of Energy's National Nuclear Security Administration
Copyright © 2006-2017 LANS LLC All rights reserved | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health